A phase I trial of CORT118335 for non-alcoholic fatty-liver disease and other metabolic disorders.

Trial Profile

A phase I trial of CORT118335 for non-alcoholic fatty-liver disease and other metabolic disorders.

Planning
Phase of Trial: Phase I

Latest Information Update: 01 Aug 2017

At a glance

  • Drugs CORT 118335 (Primary)
  • Indications Metabolic disorders; Non-alcoholic fatty liver disease
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Aug 2017 According to a Corcept Pharmaceuticals media release, this trial is expected to begin this month.
    • 08 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top